Cargando…

Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine

Prostate adenocarcinoma (PRAD) is a leading cause of death among men. Messenger ribonucleic acid (mRNA) vaccine presents an attractive approach to achieve satisfactory outcomes; however, tumor antigen screening and vaccination candidates show a bottleneck in this field. We aimed to investigate the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Xiaonan, Xu, Hang, Yi, Xianyanling, Zhang, Tianyi, Wei, Qiang, Li, Hong, Ai, Jianzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645679/ https://www.ncbi.nlm.nih.gov/pubmed/34872584 http://dx.doi.org/10.1186/s12943-021-01452-1

Ejemplares similares

Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma
por: Xu, Hang, et al.
Publicado: (2021)

IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer
por: Yi, Xianyanling, et al.
Publicado: (2022)

Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy
por: Yi, Xianyanling, et al.
Publicado: (2023)

Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development
por: Ye, Liguo, et al.
Publicado: (2021)

Vitamin E intake and multiple health outcomes: an umbrella review
por: Zhang, Tianyi, et al.
Publicado: (2023)

Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine
por: Sun, Zhuolun, et al.
Publicado: (2023)

Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development
por: Huang, Xing, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development
por: Xu, Ran, et al.
Publicado: (2022)

Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development
por: Wang, Guixin, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development
por: Lu, Tai-Liang, et al.
Publicado: (2023)

SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs
por: Xu, Hang, et al.
Publicado: (2022)

Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens
por: Fang, Zhenhao, et al.
Publicado: (2023)

Mutator-Derived lncRNA Landscape: A Novel Insight Into the Genomic Instability of Prostate Cancer
por: Tang, Liansha, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development
por: Huang, Xing, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development
por: Lin, Han, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development
por: Chen, Zhuohui, et al.
Publicado: (2022)

Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma
por: Zhao, Deze, et al.
Publicado: (2022)

Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
por: Gui, Cheng-Peng, et al.
Publicado: (2022)

Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome
por: Li, Jin, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development
por: Li, Ruo Qi, et al.
Publicado: (2022)

Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development
por: Wang, Shuhang, et al.
Publicado: (2022)

The global mRNA vaccine patent landscape
por: Li, Mengyao, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Neo-Antigen mRNA Vaccines
por: Esprit, Arthur, et al.
Publicado: (2020)

Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
por: Ma, Shuai, et al.
Publicado: (2021)

Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma
por: Zhou, Quanwei, et al.
Publicado: (2021)

Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development
por: Ye, Liguo, et al.
Publicado: (2021)

Identification of Tumor Antigens and Design of mRNA Vaccine for Colorectal Cancer Based on the Immune Subtype
por: Liu, Cong, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development
por: Wang, Fan
Publicado: (2023)

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer
por: Wei, Yuanfeng, et al.
Publicado: (2023)

Identifying tumor antigens and immuno‐subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine
por: Tan, Huaicheng, et al.
Publicado: (2022)

Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma
por: Zhang, Shichao, et al.
Publicado: (2022)

Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine
por: Zhong, Hua, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development
por: Lu, Tong, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes in lung squamous cell carcinoma for mRNA vaccine development
por: Zhao, Jiaying, et al.
Publicado: (2022)

Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination
por: You, Weiqiang, et al.
Publicado: (2022)

Myocarditis and COVID-19 mRNA vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Extracorporeal Shock Wave Lithotripsy and Flexible Ureteroscopy for Treatment of Urolithiasis in Horseshoe Kidney Patients: A Systematic Review and Meta-Analysis
por: Yi, Xianyanling, et al.
Publicado: (2021)

Humoral response to a fourth dose of mRNA vaccine in kidney transplant recipient responders to three doses of mRNA vaccine
por: de Nattes, Tristan, et al.
Publicado: (2022)

Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma
por: Wu, Changwu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_je2l4uvgh0um0v49o796uemsks